

Cystic fibrosis – lumacaftor+ivacaftor or tezacaftor+ivacaftor – continuing authority application

Online PBS Authorities



You do not need to complete this form if you use the **Online PBS Authorities** system.

For more information and how to access the **Online PBS Authorities** system, go to servicesaustralia.gov.au/hppbsauthorities

When to use this form

Use this form to apply for **continuing** PBS-subsidised lumacaftor+ivacaftor or tezacaftor+ivacaftor for patients with cystic fibrosis.

Important information

Continuing authority applications can be made using the **Online PBS Authorities system** or in writing and must include sufficient information to determine the patient's eligibility according to the PBS criteria.

Under no circumstances will phone approvals be granted for cystic fibrosis **continuing** authority applications.

The information in this form is correct at the time of publishing and may be subject to change.

Continuing treatment

This form is **ONLY** for **continuing** treatment.

The patient remains eligible to receive continuing treatment providing they continue to sustain a response to treatment.

Section 100 arrangements for lumacaftor+ivacaftor and tezacaftor+ivacaftor

These items are available to a patient who is attending:

- an approved private hospital, **or**
- a public hospital

and is a:

- day admitted patient
- non-admitted patient, **or**
- patient on discharge.

These items are not available as a PBS benefit for in-patients of a public hospital.

The hospital name and provider number must be included in this authority form.

For more information

Go to servicesaustralia.gov.au/healthprofessionals

Cystic fibrosis – lumacaftor+ivacaftor or tezacaftor+ivacaftor – continuing authority application

Online PBS Authorities



You do not need to complete this form if you use the **Online PBS Authorities** system.

Go to servicesaustralia.gov.au/hppbsauthorities

Patient's details

1 Medicare card number

Ref no.

or

Department of Veterans' Affairs card number

2 Family name

First given name

3 Date of birth (DD MM YYYY)

Prescriber's details

4 Prescriber number

5 Family name

First given name

6 Business phone number (including area code)

Alternative phone number (including area code)

Hospital details

7 Hospital name

This hospital is a:

☐ public hospital

☐ private hospital

8 Hospital provider number

Conditions and criteria

To qualify for PBS authority approval, the following conditions must be met.

9 This application is for:

☐ lumacaftor+ivacaftor **▶ Go to 11**

or

☐ tezacaftor+ivacaftor

10 The patient:

☐ is homozygous for the F508del mutation

or

☐ has at least one residual function (RF) mutation

11 The patient is being treated:

☐ by a specialist respiratory physician with expertise in cystic fibrosis

or

☐ in consultation with a specialist respiratory physician with expertise in cystic fibrosis (if attendance is not possible due to geographic isolation).

12 The patient is being treated:

☐ in a centre with expertise in cystic fibrosis

or

☐ in consultation with a centre with expertise in cystic fibrosis (if attendance is not possible due to geographic isolation).

13 Is this treatment being used as sole PBS-subsidised cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy for this condition?

Yes ☐

No ☐



MCA0PB244 2506

14 Will the treatment be given concomitantly with standard therapy for this condition?

Yes ☐

No ☐

15 The patient, applying for:

☐ **lumacaftor+ivacaftor**, is **not** currently receiving one of the strong CYP3A4 inducers outlined in the Product Information

or

☐ **tezacaftor+ivacaftor**, is **not** currently receiving one of the CYP3A4 inducers listed in the restrictions

16 Provide current CYP3A4 inhibitors, CYP3A4 inducers and IV antibiotics, if applicable

Checklist

17  The relevant attachments need to be provided with this form.

☐ Details of the proposed prescription(s).

Privacy notice

18 Personal information is protected by law (including the *Privacy Act 1988*) and is collected by Services Australia for the purposes of assessing and processing this authority application. Personal information may be used by Services Australia, or given to other parties where the individual has agreed to this, or where it is required or authorised by law (including for the purpose of research or conducting investigations).

More information about the way in which Services Australia manages personal information, including our privacy policy, can be found at servicesaustralia.gov.au/privacypolicy

Prescriber's declaration

You do not need to **sign** the declaration if you complete this form using Adobe Acrobat Reader and return this form through Health Professional Online Services (HPOS) at servicesaustralia.gov.au/hpos

19 I declare that:

- I am aware that this patient must meet the criteria listed in the current Schedule of Pharmaceutical Benefits to be eligible for this medicine
- I have informed the patient that their personal information (including health information) will be disclosed to Services Australia for the purposes of assessing and processing this authority application
- I have provided details of the proposed prescription(s) and the relevant attachments as specified in the Pharmaceutical Benefits Scheme restriction
- the information I have provided in this form is complete and correct.

I understand that:

- giving false or misleading information is a serious offence.

☐ I have read, understood and agree to the above.

Date (DD MM YYYY) (you **must** date this declaration)

--	--	--	--	--	--	--	--	--	--

Prescriber's signature (**only** required if returning by post)



Returning this form

Return this form, details of the proposed prescription(s) and any relevant attachments:

- **online** (no signature required), upload through HPOS at servicesaustralia.gov.au/hpos
or
- by post (signature required) to
Services Australia
Complex Drugs Programs
Reply Paid 9826
HOBART TAS 7001